CalciMedica, Inc. — Investor Relations & Filings
CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for acute inflammatory and immunologic diseases. The company specializes in the inhibition of calcium release-activated calcium (CRAC) channels, a therapeutic approach designed to modulate the immune response and protect against tissue cell injury. Its lead product candidate, Auxora™, is an intravenous formulation of the proprietary small molecule CRAC channel inhibitor, zegocractin. CalciMedica is developing Auxora for the treatment of life-threatening conditions with high unmet medical needs, including acute kidney injury (AKI) with respiratory failure and acute pancreatitis (AP), for which there are currently no approved disease-modifying treatments.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - CalciMedica, Inc. (0001534133) (Filer) | 2026-05-12 | English | |
| 10-K/A - CalciMedica, Inc. (0001534133) (Filer) | 2026-04-30 | English | |
| S-3 - CALCIMEDICA, INC. (0001534133) (Filer) | 2026-03-03 | English | |
| 10-K - CALCIMEDICA, INC. (0001534133) (Filer) | 2026-03-03 | English | |
| 8-K - CALCIMEDICA, INC. (0001534133) (Filer) | 2026-03-03 | English | |
| SCHEDULE 13G/A Filing | 2026-02-06 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
8 filings
| |||||
| 45231608 | 8-K - CalciMedica, Inc. (0001534133) (Filer) | 2026-05-12 | English | ||
| 39208161 | 10-K/A - CalciMedica, Inc. (0001534133) (Filer) | 2026-04-30 | English | ||
| 32893525 | S-3 - CALCIMEDICA, INC. (0001534133) (Filer) | 2026-03-03 | English | ||
| 32893526 | 10-K - CALCIMEDICA, INC. (0001534133) (Filer) | 2026-03-03 | English | ||
| 32893524 | 8-K - CALCIMEDICA, INC. (0001534133) (Filer) | 2026-03-03 | English | ||
| 30430142 | SCHEDULE 13G/A Filing | 2026-02-06 | English | ||
| 30430167 | 8-K Filing | 2026-01-28 | English | ||
| 30430145 | 8-K Filing | 2026-01-28 | English | ||
|
2025
7 filings
| |||||
| 12507329 | Major Shareholding Notification 2025 | 2025-12-01 | English | ||
| 12507327 | 10-Q | 2025-11-12 | English | ||
| 12507326 | 8-K | 2025-11-12 | English | ||
| 12507328 | Major Shareholding Notification 2025 | 2025-11-07 | English | ||
| 12507330 | 8-K | 2025-11-06 | English | ||
| 12507332 | 424B5 | 2025-11-06 | English | ||
| 12507334 | Major Shareholding Notification 2025 | 2025-10-29 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Amylyx Pharmaceuticals, Inc.
Develops therapies for neurodegenerative diseases and other…
|
AMLX | US | Manufacturing |
|
AN2 Therapeutics, Inc.
Biopharmaceutical firm developing boron-based drugs for inf…
|
ANTX | US | Manufacturing |
|
Ananda Pharma Plc
Biopharmaceutical firm developing cannabinoid-based medicin…
|
ANAN | GB | Manufacturing |
|
ANATOLİA TANI VE BİYOTEKNOLOJİ ÜRÜNLERİ ARAŞTIRMA GELİŞTİRME SANAYİ VE TİCARET A.Ş.
Designs, develops, and manufactures molecular diagnostic so…
|
ANGEN | TR | Manufacturing |
|
ANAVEX LIFE SCIENCES CORP.
Clinical-stage biopharmaceutical company developing therape…
|
AVXL | US | Manufacturing |
|
Anbio Biotechnology
Develops and provides in-vitro diagnostic (IVD) solutions a…
|
NNNN | KY | Manufacturing |
|
Anebulo Pharmaceuticals, Inc.
Clinical-stage biotech developing therapies for acute canna…
|
ANEB | US | Manufacturing |
|
AnGes, Inc.
Biopharmaceutical firm developing gene-based and nucleotide…
|
4563 | JP | Manufacturing |
|
ANG Lifesciences India Limited
Develops and manufactures sterile dry powder and liquid inj…
|
540694 | IN | Manufacturing |
|
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.
Develops biopharmaceuticals, genetic engineering products, …
|
300009 | CN | Manufacturing |
CalciMedica, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34649/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34649 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34649 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34649 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34649}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for CalciMedica, Inc. (id: 34649)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.